Chinical efficacy of edaravone on acute cerebral hemorrhage
Wang Guodong
Abstract
Wang Guodong
Abstract
Objective To evaluate the efficacy of edaravone,a novel hydroxy-free radical scavenger,on the treatment of acute cerebral hemorrhage(CH). Methods 71 CH cases enrolled within 48h of onset were divided into treatment group(n=36) and control group(n=35) randomly. Edaravone was infused at a dose of 30mg,twice a day,for 14 days. Meanwhile,the dehydrater(mannitol and or albumin) were taken as basic treatment. The therapies of the placebo group were similar to those of Edaravone group except for Edaravone. Before treatment and at 30th day after treatment,the neurological deficits and activities of daily living were evaluated using European Stroke Scale(ESS). All the patients were followed up for survival at 30th dav the increase rate of ESS was evaluated. There were significan difference between Edaravone group(48.2±16.4)% and the placebo group (29.7±11.1)% (P0.001). Conclusions Edaravone is a new effective neuroprotective agent for treating CH.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To evaluate the efficacy of edaravone,a novel hydroxy-free radical scavenger,on the treatment of acute cerebral hemorrhage(CH). Methods 71 CH cases enrolled within 48h of onset were divided into treatment group(n=36) and control group(n=35) randomly. Edaravone was infused at a dose of 30mg,twice a day,for 14 days. Meanwhile,the dehydrater(mannitol and or albumin) were taken as basic treatment. The therapies of the placebo group were similar to those of Edaravone group except for Edaravone. Before treatment and at 30th day after treatment,the neurological deficits and activities of daily living were evaluated using European Stroke Scale(ESS). All the patients were followed up for survival at 30th dav the increase rate of ESS was evaluated. There were significan difference between Edaravone group(48.2±16.4)% and the placebo group (29.7±11.1)% (P0.001). Conclusions Edaravone is a new effective neuroprotective agent for treating CH.
Key concepts: Edaravone, Medicine, Free radical scavenger, Placebo, Anesthesia, Mannitol, Placebo group, Neuroprotection